Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin
Tyrosine kinase inhibitors (TKIs) induce autophagy in many types of cancer cells. We previously reported that gefitinib (GEF) and imatinib (IMA) induce autophagy in epidermal growth factor receptor (EGFR) knock-out A549 and non-BCR-ABL-expressing leukemia cell lines, respectively. This evidence sugg...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-07-01
|
Series: | Biochemistry and Biophysics Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405580820300595 |
id |
doaj-c639655190624e29aa720337aaa658e3 |
---|---|
record_format |
Article |
spelling |
doaj-c639655190624e29aa720337aaa658e32020-11-25T03:03:50ZengElsevierBiochemistry and Biophysics Reports2405-58082020-07-0122Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycinHideki Tanaka0Hirotsugu Hino1Shota Moriya2Hiromi Kazama3Masaya Miyazaki4Naoharu Takano5Masaki Hiramoto6Kiyoaki Tsukahara7Keisuke Miyazawa8Department of Otolaryngology (Head and Neck Surgery), Tokyo Medical University Hospital, 6-7-1, Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, JapanDepartment of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, JapanDepartment of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, JapanDepartment of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, JapanDepartment of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, JapanDepartment of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, JapanDepartment of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, JapanDepartment of Otolaryngology (Head and Neck Surgery), Tokyo Medical University Hospital, 6-7-1, Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, JapanDepartment of Biochemistry, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan; Corresponding author.Tyrosine kinase inhibitors (TKIs) induce autophagy in many types of cancer cells. We previously reported that gefitinib (GEF) and imatinib (IMA) induce autophagy in epidermal growth factor receptor (EGFR) knock-out A549 and non-BCR-ABL-expressing leukemia cell lines, respectively. This evidence suggests that TKI-induced autophagy is independent of the original target molecules. The present study compared the autophagy-inducing abilities of various TKIs, regardless of their targets, by quantitative autophagy flux assay. We established stable clones expressing the GFP-LC3-mCherry-LC3ΔG plasmid in A549, PC-9, and CAL 27 cell lines and assessed autophagy inducibility by monitoring the fluorescent ratios of GFP-LC3 to mCherry-LC3ΔG using an IncuCyte live cell imaging system during exposure to TKIs viz; GEF, osimertinib (OSI), lapatinib (LAP), lenvatinib (LEN), sorafenib (SOR), IMA, dasatinib (DAS), and tivantinib (TIV). Among these TKIs, DAS, GEF, and SOR exhibited prominent autophagy induction in A549 and PC-9 cells. In CAL 27 cells, IMA, SOR, and LEN, but not GEF, TIV, or OSI, exhibited autophagy induction. In the presence of azithromycin (AZM), which showed an inhibitory effect on autophagy flux, TKIs with prominent autophagy inducibility exhibited enhanced cytotoxicity via non-apoptotic cell death relative to effects of TKI alone. Therefore, autophagy inducibility of TKIs differed in the context of cancer cells. However, once induced, they appeared to have cytoprotective functions. Thus, blocking TKI-induced autophagy with AZM may improve the therapeutic effect of TKIs in cancer cells.http://www.sciencedirect.com/science/article/pii/S2405580820300595Tyrosine kinase inhibitorAutophagyMacrolide antibioticsCancer |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hideki Tanaka Hirotsugu Hino Shota Moriya Hiromi Kazama Masaya Miyazaki Naoharu Takano Masaki Hiramoto Kiyoaki Tsukahara Keisuke Miyazawa |
spellingShingle |
Hideki Tanaka Hirotsugu Hino Shota Moriya Hiromi Kazama Masaya Miyazaki Naoharu Takano Masaki Hiramoto Kiyoaki Tsukahara Keisuke Miyazawa Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin Biochemistry and Biophysics Reports Tyrosine kinase inhibitor Autophagy Macrolide antibiotics Cancer |
author_facet |
Hideki Tanaka Hirotsugu Hino Shota Moriya Hiromi Kazama Masaya Miyazaki Naoharu Takano Masaki Hiramoto Kiyoaki Tsukahara Keisuke Miyazawa |
author_sort |
Hideki Tanaka |
title |
Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin |
title_short |
Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin |
title_full |
Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin |
title_fullStr |
Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin |
title_full_unstemmed |
Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin |
title_sort |
comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin |
publisher |
Elsevier |
series |
Biochemistry and Biophysics Reports |
issn |
2405-5808 |
publishDate |
2020-07-01 |
description |
Tyrosine kinase inhibitors (TKIs) induce autophagy in many types of cancer cells. We previously reported that gefitinib (GEF) and imatinib (IMA) induce autophagy in epidermal growth factor receptor (EGFR) knock-out A549 and non-BCR-ABL-expressing leukemia cell lines, respectively. This evidence suggests that TKI-induced autophagy is independent of the original target molecules. The present study compared the autophagy-inducing abilities of various TKIs, regardless of their targets, by quantitative autophagy flux assay. We established stable clones expressing the GFP-LC3-mCherry-LC3ΔG plasmid in A549, PC-9, and CAL 27 cell lines and assessed autophagy inducibility by monitoring the fluorescent ratios of GFP-LC3 to mCherry-LC3ΔG using an IncuCyte live cell imaging system during exposure to TKIs viz; GEF, osimertinib (OSI), lapatinib (LAP), lenvatinib (LEN), sorafenib (SOR), IMA, dasatinib (DAS), and tivantinib (TIV). Among these TKIs, DAS, GEF, and SOR exhibited prominent autophagy induction in A549 and PC-9 cells. In CAL 27 cells, IMA, SOR, and LEN, but not GEF, TIV, or OSI, exhibited autophagy induction. In the presence of azithromycin (AZM), which showed an inhibitory effect on autophagy flux, TKIs with prominent autophagy inducibility exhibited enhanced cytotoxicity via non-apoptotic cell death relative to effects of TKI alone. Therefore, autophagy inducibility of TKIs differed in the context of cancer cells. However, once induced, they appeared to have cytoprotective functions. Thus, blocking TKI-induced autophagy with AZM may improve the therapeutic effect of TKIs in cancer cells. |
topic |
Tyrosine kinase inhibitor Autophagy Macrolide antibiotics Cancer |
url |
http://www.sciencedirect.com/science/article/pii/S2405580820300595 |
work_keys_str_mv |
AT hidekitanaka comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin AT hirotsuguhino comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin AT shotamoriya comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin AT hiromikazama comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin AT masayamiyazaki comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin AT naoharutakano comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin AT masakihiramoto comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin AT kiyoakitsukahara comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin AT keisukemiyazawa comparisonofautophagyinducibilityinvarioustyrosinekinaseinhibitorsandtheirenhancedcytotoxicityviainhibitionofautophagyincancercellsincombinedtreatmentwithazithromycin |
_version_ |
1724684238914060288 |